AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RYTM · NASDAQ · Biotechnology

Rhythm Pharmaceuticals (RYTM)

Markets IMCIVREE and develops MC4R agonists for rare neuroendocrine obesity disorders.

$99.27

After hours−0.16 (−0.16%)

At close$99.43(+0.60%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	23	24	26	29	33	42	33	49	51	57	60	71
Cost of revenue	2	3	3	3	4	4	4	6	5	5	7	9
Gross profit	20	21	23	26	29	38	29	43	46	52	53	62
	64	62	163	67	73	79	76	88	98	100	105	111
Research & development	34	30	128	30	38	41	37	42	46	42	42	43
Selling, general & administrative	30	32	34	36	35	38	39	46	52	57	64	67
Operating income	−44	−41	−140	−40	−44	−41	−47	−45	−53	−47	−52	−49
	0	0	−1	9	0	−2	−2	−1	0	0	−3	0
Interest income	3	4	3	4	4	4	4	3	4	4	4	3
Interest expense	3	5	5	5	5	5	5	6	5	5	5	5
Other non-operating income	−3	−4	−4	−13	−5	−3	−3	−5	−5	−4	−2	−4
Income before tax	−44	−41	−141	−32	−44	−43	−49	−46	−53	−48	−55	−49
Income tax expense	0	0	0	0	0	0	0	0	0	0	1	0
Net income from continuing operations	−44	−42	−141	−32	−44	−43	−49	−47	−53	−48	−56	−49
Net income	−44	−42	−141	−32	−44	−43	−49	−47	−53	−48	−56	−49
EPS, basic	−$0.76	−$0.70	−$2.35	−$0.53	−$0.71	−$0.72	−$0.81	−$0.75	−$0.82	−$0.73	−$0.83	−$0.73
EPS, diluted	−$0.76	−$0.70	−$2.35	−$0.53	−$0.71	−$0.72	−$0.81	−$0.75	−$0.82	−$0.73	−$0.83	−$0.73
Weighted average shares, basic	58	59	60	61	61	62	63	64	64	67	68	69
Weighted average shares, diluted	58	59	60	61	61	62	63	64	64	67	68	69
EBITDA	−40	−36	−136	−27	−38	−38	−44	−40	−48	−43	−50	−44
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−41	−37	−136	−27	−39	−38	−44	−40	−48	−43	−51	−44